部分新药的配伍禁忌

随着科学技术的发展,新的药物不断出现,而新药的配伍在静脉药物“禁忌表”中查不到,但在临床应用中,某些新药在与其它药物静脉接输、静脉推注或静脉入壶时,出现混浊沉淀的现象时有发生。笔者现将发现配伍时出现不良反应的部分新药做一简介:1加替沙星(丰海甘、艾尔嘉)与优普酮(注射用头孢派酮钠、舒巴坦钠)配伍立即呈白色混浊,静止后出现白色絮状沉淀;与清开灵注射液配伍呈现混浊,静止后出现少量漂浮物;与痰热清注射液配伍立即呈白色混浊,随即出现白色絮状沉淀。2万古霉素与美平(美罗培南)配伍立即呈白色混浊,静止后出现白色沉淀;与优普酮配…     

中西医结合治疗再生障碍性贫血157例临床观察

目的探讨黄芪注射液、及黄芪注射液加多抗甲素配伍应用治疗再生障碍性贫血(AA)的疗效。方法黄芪组61例,黄芪注射液加多抗甲素组33例,对照组63例,治疗组在中西医结合治疗基础上加用黄芪注射液或黄芪注射液加多抗甲素,对照组采用中西医常规治疗,三组均经系统治疗6个月以上。结果黄芪组总有效率86.8%,黄芪注射液加多抗甲素组总有效率90.9%,对照组总有效率65.1%,黄芪组、黄芪注射液加多抗甲素组与对照组比较均有显著性差异(P<0.05);黄芪组与黄芪加多抗甲素组比较有显著性差异(P<0.05)。结论黄芪注射液、黄芪加多抗甲素治疗再生障碍性贫血均是通过调节机体免疫功能起效。     

大剂量黄芪注射液治疗以蛋白尿为主难治性紫癜肾8例临床体会

我们2004年1月～2006年6月共收治以蛋白尿为主要表现的难治性紫癜肾8例，应用大剂量黄芪注射液治疗而收到满意疗效。现报告如下。     

Clinical study on effect of Astragalus Injection (黄芪注射液) and its immuno-regulation action in treating chronic aplastic anemia

Objective:To observe the clinical effect of Astragalus Injection(黄芪注射液,AI) and its immuno-regulatory action in treating chronic aplastic anemia(CAA).Methods:Sixty patients with CAA were randomly assigned to two groups equally,both were treated with Stanozolol three times a day,2 mg each time through oral intake,but AI was given additionally to the patients in the treated group once a day via intravenous dripping.All were treated for 15 days as one therapeutic course and the whole medication lasted for more than 4 months totally,with follow-up adopted.The clinical effi cacy was estimated and the changes of T-lymphocyte subsets in peripheral blood as well as the serum levels of tumor necrosis factor-α(TNF-α) and interleukin-2(IL-2) were observed.Results:The total effective rate in the treated group was 83.3%(25/30),which was higher than that in the control group 66.7%(20/30),showing significant difference between them(P<0.05).Levels of hemoglobin,WBC,reticular cell and platelet were elevated in both groups after treatment,but the improvement was signif icantly better in the treated group than that in the control group with respect to the former three indexes(P<0.05).The level of CD4 increased and that of CD8 decreased signifi cantly after treatment in the treated group(P<0.05),which showed significant difference as compared with those in the control group(P<0.05).Levels of serum TNF-α and IL-2 lowered after treatment in both groups,but signifi cance only showed in the treated group(P<0.05).The degree of proliferation in bone marrow got raised signifi cantly and the percentage of non-hemopoietic cells reduced signifi cantly in the treated group after treatment,also showing significant difference to those in the control group(P<0.05).Conclusion:AI could promote the recovery of hemopoietic function,which might be through improving T-lymphocyte subsets and reducing the release of negative regulatory factors such as TNF-α and IL-2 to alleviate the inhibition on hemopoietic function.     

黄芪注射液联合多抗甲素治疗再生障碍性贫血33例

2000年1月-2003年10月,我们在采用常规治疗的基础上加用黄芪注射液和多抗甲素治疗再生障碍性贫血（下简称再障）33例,并与常规治疗的基础加用黄芪注射液治疗的35例作对照,现报道如下.     

特发性血小板减少性紫癜的中西医治疗进展

特发性血小板减少性紫癜 (ITP)是以出血及外周血小板减少 ,骨髓巨核细胞数正常或增多并伴有成熟障碍为主要表现的常见出血性疾病。目前已公认本病是一种由于患者体内产生自身抗血小板抗体 ,致使血小板寿命缩短 ,破坏过多 ,数量减少为病理特征的自身免疫性疾病。 ITP按病程长短可分为急性型和慢性型两种 ,在疾病早期很难鉴别 ,两者病因病机及转归迥然不同。儿童 80 %为急性型 (AITP) ,无性别差异 ,冬春两季易发病 ,多数有病毒感染史 ,为自限性疾病 ,一般认为是急性病毒感染后的一种天然免疫反应 ,一但病源清除 ,疾病在 6个月～ 12个月痊…     

大剂量复方丹参注射液治疗急性白血病并发弥散性血管内凝血24例

弥散性血管内凝血（ＤＩＣ）是急性白血病（ＡＬ）严重并发症之一。临床以出血、溶血、栓塞、休克为主要特征，如不及时治疗，常常导致内脏出血而死亡，与ＡＬ的预后密切相关。自１９９１年７月～１９９８年１０月，我院应用大剂量复方丹参注射液治疗 ＡＬ并发 ＤＩＣ ２４例，疗效满意，现报告如下。 临床资料 １　　病例选择　２４例均为住院患者，其中男８例，女１６例，年龄１６～４６岁，平均２１．９岁；ＡＬ亚型各为Ｍ２ａ２例，Ｍ３　１７例，Ｍ４１例，急性淋巴性白血病（ＡＬＬ）３例，白血病前期１例。临 床表现：均有严重的皮肤…     

VAMP方案并辨证施治治疗成人急性淋巴细胞白血病120例疗效观察

ＶＡＭＰ方案并辨证施治治疗成人急性淋巴细胞白血病１２０例疗效观察李振丽，王继亮（河北省廊坊市血液病研究所１０２８００）我院自１９８６～１９９３年间，共收治成人急性淋巴细胞白血病１４３例，可供疗效统计１２０例，结合中医辨证施治，进一步提高了缓解率。初治...     

骨髓增生异常综合征中医证候学分证50例探究

骨髓增生异常综合征(myelodysplasticsyndromes,MDS)是一组以难治性血细胞质、量异常和高风险发展为急性白血病为特征的恶性克隆性造血干细胞疾病.     

益气解毒活血法联合化疗对成人AML缓解后长无病生存期的影响

1临床资料 120例急性髓细胞白血病（AML）均为我院1996-01～2004—12住院病人，按数字表法随机分为治疗组和对照组。治疗组60例，男33例，女27例；年龄18～65岁，平均年龄35．63岁；对照组60例，男31例，女29例；年龄19～67岁，平均36．57岁；两组资料经统计学检验无显著性差异（P〉0．05）。诊断标准：参照《血液病诊断及疗效判断标准）之急性白血病诊断标准。